Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BHT004IB
- Development stage
- Preclinical
- Lead developer
- Bio-Hybrid Therapeutics
- Modality
- Antibody-Based Therapeutics
01
Overview
BHT004IB is a pipeline-stage biologic antibody candidate being developed by Bio-Hybrid Therapeutics. It is designed to target and address allergic disease pathways associated with irritable bowel syndrome (IBS). By intervening in these specific allergic pathways, BHT004IB aims to provide a targeted therapeutic approach for patients suffering from IBS-related allergic symptoms, moving beyond traditional symptom management to address underlying immunological mechanisms.
Beyond the preview
Go deeper on BHT004IB.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BHT004IB.